|1.||Andriole, Gerald L: 3 articles (12/2012 - 05/2010)|
|2.||Parekh, Dipen J: 3 articles (01/2011 - 05/2009)|
|3.||Fleshner, Neil: 2 articles (08/2013 - 09/2006)|
|4.||Su, Zhen: 2 articles (05/2013 - 03/2013)|
|5.||Sayani, Amyn: 2 articles (05/2013 - 03/2013)|
|6.||Kruep, Eric J: 2 articles (05/2013 - 05/2011)|
|7.||Chaudhari, Sham: 2 articles (05/2013 - 08/2012)|
|8.||Eaddy, Michael: 2 articles (12/2012 - 08/2012)|
|9.||Kattan, Michael W: 2 articles (01/2012 - 01/2010)|
|10.||Shah, Manan B: 2 articles (05/2011 - 02/2007)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
05/01/1998 - "A convenient and rapid in vitro model to screen steroid 5 alpha-reductase inhibitors, which are effective in the treatment of benign prostatic hyperplasia (BPH), was developed. "
01/01/2003 - "Recent studies have both clarified and extended the roles of 5 alpha-reductase inhibitors in benign prostatic hyperplasia, and these may expand further if chemopreventive abilities are proved. "
06/01/2014 - "Alpha-blockers and 5-alpha reductase inhibitors are common drugs used to treat benign prostatic hyperplasia (BPH), a prevalent problem in older men associated with significant morbidity and cost. "
01/01/2013 - "Treatment with 5-alpha reductase inhibitors (5ARI) is commonly utilized for the treatment of benign prostatic hyperplasia (BPH). "
12/01/2012 - "Establishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients."
05/01/2013 - "It is unclear how evidence demonstrating the efficacy of combination 5-alpha reductase inhibitors and alpha blockers for improving symptoms and reducing risk of disease progression translates into real-world practice for the treatment of BPH. "
05/01/2011 - "Many clinicians use alpha-blockers for rapid symptom control, later adding 5-alpha reductase inhibitors to modify long-term disease progression. "
01/01/2003 - "The ability of 5 alpha-reductase inhibitors to prevent disease progression was also confirmed. "
03/01/2007 - "Trials of monotherapy with alpha(1)-adrenergic-receptor antagonists (alpha(1)ARAs) and 5 alpha-reductase inhibitors (5ARIs) have found that the former drug class is effective in managing benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) and improving the maximal urinary flow rate in shortand long-term treatment, regardless of prostate size, whereas the latter drug class is effective in reducing prostate size and preventing disease progression in longer-term treatment. "
01/01/2005 - "5-alpha Reductase inhibitors have proven useful for the prevention of BPH progression as measured by prostate volume, disease progression, incidence of acute urinary retention and the need for subsequent BPH-related surgery. "
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2014 - "Two large, population-based, phase 3 prostate cancer prevention trials reported that 5-alpha reductase inhibitors significantly reduce prostate cancer risk. "
05/01/2013 - "5-alpha Reductase inhibitors in prostate cancer: from clinical trials to clinical practice."
12/01/2012 - "Recent studies demonstrated that 5-alpha reductase inhibitors could reduce not only the prostate volume but also the volume of Gleason grade 3 prostate cancer, which made easier the detection of higher-grade prostate cancer in the second biopsy. "
12/01/2012 - "Trials on 5-alpha reductase inhibitors in prostate cancer prevention showed that they could significantly decrease the incidence of prostate cancer, but meanwhile increase high-grade cases as well. "
11/01/2009 - "Further studies will specify efficacy and safety of 5-alpha reductase inhibitors in prevention of prostatic cancer."
01/01/1987 - "These studies suggest that 4MA is effective in inhibiting the growth of human androgen-responsive tumors grown in athymic nude mice and that further studies with other 5 alpha-reductase inhibitors are indicated."
07/01/2014 - "Our recent studies suggested that the administration of 5 alpha-reductase inhibitors during the off-cycle of IADT can significantly prolong the survival of mice bearing androgen-sensitive prostate tumors when off-cycle duration was short. "
09/01/2006 - "It is our opinion that among men who warrant 5-alpha reductase inhibitors (5ARIs) as part of their benign prostatic hyperplasia regimen, cancer prevention should be recognized as an additional benefit of treatment. "
01/01/1992 - "The efficacy and safety of 5 alpha-reductase inhibitors in studies to date, combined with the androgen dependence of tumor production, strongly supports investigating their use for chemoprevention of prostate cancer."
01/01/2011 - "Thus far, only the studies on 5 alpha-reductase inhibitors (the Prostate Cancer Prevention Trial [PCPT] and Reduction by Dutasteride of Prostate Cancer Events [REDUCE] trial) have demonstrated a reduction in the risk of PCa, while results from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) concluded no decreased risk for PCa with selenium or vitamin E."
05/01/2011 - "Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. "
04/01/1992 - " Benign prostate hyperplasia previously manageable only by surgery can respond favorably to 5 alpha-reductase inhibitors and/or selective alpha-adrenergic blockers in some patients according to recent data."
|6.||Androgen Antagonists (Antiandrogens)
|7.||Prostate-Specific Antigen (Semenogelase)
|1.||Transurethral Resection of Prostate (TURP)
|3.||Drug Therapy (Chemotherapy)